Medical cannabis company EMMAC Life Sciences Ltd said on Tuesday that its EMMAC UK Limited UK subsidiary has completed the acquisition of the entire issued share capital of Rokshaw Limited.

Upon closing, the acquisition brings immediate revenues to EMMAC as well as enables to import medical cannabis into the UK to meet the growing demands of the market, led by regulatory change, for premium medical cannabis product.

Rokshaw is reportedly EMMAC's second GMP-certified laboratory following the acquisition of Medalchemy, its research and development facility in Spain. This unique vertical integration allows EMMAC to control both the Active Pharmaceutical Ingredient and Finished Good Manufacture.

Based in Sunderland, UK, Rokshaw is a manufacturer of a wide range of Specials bespoke to patient requirements in an EU GMP environment to ensure that patients across the UK receive the highest quality products. It already manufactured more than 6,000 formulations for over 2,000 pharmacies and hospitals across the UK.

Additionally, Rokshaw holds the following licenses: MHRA Specials Manufacturing, Home Office Controlled drugs schedule 2 and Wholesale dealers authorisation, which ensure that compliant product can be imported and manufactured in the UK in order to meet growing demands for cannabis-based products for medicinal use (CBPMs). Rokshaw is pursuing additional licenses to facilitate greater research into the benefits of CBPMs.